Publications by authors named "A Borhani Haghighi"
Background: Blastocystis is a prevalent intestinal parasitic protist that infects both birds and animals. There are at least 44 subtypes (ST) of Blastocystis, with ST1-ST9 being found in humans. The correlation between specific subtypes and pathogenicity has not been definitively established.
View Article and Find Full Text PDFThis perspective discusses the convergence of digital twin (DT) technology and on-the-chip systems as pivotal innovations in precision medicine, substantially advancing drug discovery. DT leverages extensive health data to create dynamic virtual patient models, enabling predictive insights and optimized treatment strategies. Concurrently, on-the-chip systems from the Carbon world replicate human biological processes on microfluidic platforms, providing detailed insights into disease mechanisms and pharmacological interactions.
View Article and Find Full Text PDFArticle Synopsis
- - The study focuses on Facioscapulohumeral dystrophy type 1 (FSHD1), a serious muscle disorder, and emphasizes the need for a comprehensive approach to understand its genetics.
- - Researchers conducted genome sequencing and linkage analysis in a family suspected of having FSHD1, identifying a specific disease locus on chromosome 4q35.2.
- - By using advanced ultra-long-read genome sequencing, they successfully genotyped a pathogenic allele associated with FSHD1, highlighting the effectiveness of these genomic tools in disease mapping and characterization.
Introduction: Intestinal ischemia/reperfusion (I/R) injury is associated with high mortality and there is an unmet need for novel therapies. The intestinal expression of cyclooxygenase-2 (COX-2) increases rapidly after mesenteric I/R, but it is still a question of debate whether selective COX-2 inhibitors can mitigate I/R-induced gut injury. Here we aimed to compare the effect of celecoxib and rofecoxib, two selective COX-2 inhibitors, on intestinal I/R-induced injury in rats.
View Article and Find Full Text PDFBackground: MicroRNAs have gained attention as key immunomodulators, with miR-155 specifically shown in various studies to drive macrophage polarization toward the classical phenotype. This polarization is crucial, as classical macrophages play a well-recognized role in differentiating type-1 immune responses and resisting infection.
Objective: The present study aims to evaluate the anti-leishmanial immunoadjuvant effects of the miR-155 chitosan polyplex (miR-155 CP).